Version 1
: Received: 20 March 2024 / Approved: 20 March 2024 / Online: 21 March 2024 (10:42:59 CET)
Version 2
: Received: 22 March 2024 / Approved: 22 March 2024 / Online: 25 March 2024 (07:41:26 CET)
How to cite:
Figueiredo, R.G.; Duarte, N.F.V.; Campos, D.C.B.; Verduzco, M.D.J.D.; Márquez, Á.A.; De Araujo, G.T.B.; Rubin, A.S. Improving Accessibility to Patients with z0 Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America.. Preprints2024, 2024031263. https://doi.org/10.20944/preprints202403.1263.v1
Figueiredo, R.G.; Duarte, N.F.V.; Campos, D.C.B.; Verduzco, M.D.J.D.; Márquez, Á.A.; De Araujo, G.T.B.; Rubin, A.S. Improving Accessibility to Patients with z0 Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America.. Preprints 2024, 2024031263. https://doi.org/10.20944/preprints202403.1263.v1
Figueiredo, R.G.; Duarte, N.F.V.; Campos, D.C.B.; Verduzco, M.D.J.D.; Márquez, Á.A.; De Araujo, G.T.B.; Rubin, A.S. Improving Accessibility to Patients with z0 Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America.. Preprints2024, 2024031263. https://doi.org/10.20944/preprints202403.1263.v1
APA Style
Figueiredo, R.G., Duarte, N.F.V., Campos, D.C.B., Verduzco, M.D.J.D., Márquez, Á.A., De Araujo, G.T.B., & Rubin, A.S. (2024). Improving Accessibility to Patients with z0 Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America.. Preprints. https://doi.org/10.20944/preprints202403.1263.v1
Chicago/Turabian Style
Figueiredo, R.G., Gabriela Tannus Branco De Araujo and Adalberto Sperb Rubin. 2024 "Improving Accessibility to Patients with z0 Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America." Preprints. https://doi.org/10.20944/preprints202403.1263.v1
Abstract
Abstract: Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient's journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. Antifibrotic drugs are not yet available by SUS in Brazil, and the purchase is unfeasible for most of the population, which forces specialists to only offer support to patients until the treatment can get the drug. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties, but the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.
Public Health and Healthcare, Public, Environmental and Occupational Health
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
